KOSDAQBiotech & Pharma464280

Tdspharm

₩3,625▼ 5.72%2026-11-18 close
Market Cap
₩20B
Turnover
₩71,121,760
Volume
20K
Shares out.
5.5M
PER
5.2×
PBR
0.5×
EPS
₩799
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Tdspharm: sales hold, but quarterly profit keeps falling

Tdspharm's 2025 sales edged up, but operating profit has declined for four consecutive quarters from Q4 2025 through Q3 2026, so the profit trend is the key item to track.

  1. 1

    Annual sales were KRW 30 billion in 2023, KRW 27.5 billion in 2024 and KRW 27.6 billion in 2025, a marginal rise in the latest year. The operating margin fell from 16.7% in 2023 to 13.6% in 2024 and stayed at 13.6% in 2025.

  2. 2

    Operating profit in Q3 2026 was KRW 739 million, down 54.9% year on year, and profit attributable to controlling shareholders was KRW 724 million, a third straight quarterly decline.

  3. 3

    According to press coverage of an August 2026 disclosure, first-half 2026 sales reached KRW 16.1 billion, up 48% year on year, with online channels, quasi-drug sales and a price increase from Q2 cited as drivers.

  4. 4

    The patch pipeline remains mostly in research, including a buprenorphine patch preliminary study agreed in July 2026 and a keloid scar transdermal joint study agreed in June 2026, so the timing of any profit contribution looks distant.

  5. 5

    Multiples should be read against the last four quarters' combined profit attributable to controlling shareholders of KRW 4.42 billion, and while profit is falling the same share price produces a higher multiple.

02

Business structure

Tdspharm, founded in November 2002, is a transdermal drug delivery system (TDDS) specialist that mainly makes external analgesic and anti-inflammatory products for muscle pain and arthritis.

Its core products are cataplasma (poultice), plaster (adhesive patch) and patch formats, and it also produces some oral solid formulations. Because it works on an ODM basis, supplying formulations it develops to pharmaceutical companies, most finished products reach consumers under the customers' own brands.

Cataplasma accounted for about KRW 17.9 billion, or roughly 75%, of cumulative sales in the first nine months of 2026, according to a translated filing summary. The company is reported to hold a 70% share of the Korean herbal compound cataplasma market, a figure from coverage around its 2024 listing.

Its hot-melt manufacturing process, which uses thermoplastic resin rather than organic solvents, is described by the company as a core competitive strength.

Customers are pharmaceutical companies and drug wholesalers, and 2024 coverage named Jeil Health Science, Yuhan, Daewoong Pharmaceutical's peer Daeyoung Pharm, A-Pharm and JW Pharmaceutical as clients. In 2026, the company cited its online brand and quasi-drug channels as growth drivers.

New products include a mini plaster wholesale contract, a coin-type plaster and a coin-type bug patch in commercialization, plus a pharmacy-only sales channel added through a supply agreement disclosed in October 2026.

Because customers outsource formulation development, the ability to design formulations and respond quickly in production largely determines who wins orders.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩8.1B₩1.6B20.3%
2025Q4₩8.7B₩1.6B18.6%
2026Q1₩8.1B₩1.3B16.7%
2026Q2₩8.1B₩1B12.9%
2026Q3₩7.6B₩700M9.7%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2023₩30B₩5B₩4.7B16.7%20.4%48.1%
2024₩27.5B₩3.7B₩3.7B13.6%9.7%27.7%
2025₩27.6B₩3.8B₩4.3B13.6%10.0%26.6%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

Annual sales fell from KRW 30 billion in 2023 to KRW 27.5 billion in 2024, a decline of 8.4%, and then edged up to KRW 27.6 billion in 2025, a 0.4% rise that left them roughly flat. 2023 was the largest year in the period and 2024 the smallest.

Operating profit dropped from KRW 5.02 billion in 2023 to KRW 3.73 billion in 2024, a 25.7% decline, and recovered slightly to KRW 3.77 billion in 2025, up 1.0%.

Profit attributable to controlling shareholders was KRW 4.69 billion in 2023, KRW 3.72 billion in 2024 (down 20.7%) and KRW 4.27 billion in 2025 (up 15.0%), so the 2025 recovery did not return it to the 2023 level. Net profit including non-controlling interests was disclosed at the same levels for those years.

The operating margin fell from 16.7% in 2023 to 13.6% in 2024 and held at 13.6% in 2025, so the margin base stepped down after 2024.

Quarterly sales peaked at KRW 8.68 billion in Q4 2025, up 7.4% from the prior quarter, then moved to KRW 8.07 billion in Q1 2026, KRW 8.08 billion in Q2 and KRW 7.65 billion in Q3, which was down 5.4% year on year.

Operating profit fell from KRW 1.64 billion in Q3 2025 to KRW 739 million in Q3 2026, down 54.9% year on year, and it declined in each of the four quarters from Q4 2025 through Q3 2026.

Profit attributable to controlling shareholders also fell for three straight quarters after peaking at KRW 1.59 billion in Q4 2025, reaching KRW 724 million in Q3 2026, and the last four quarters combined total KRW 4.42 billion.

Operating profit as a share of quarterly sales dropped from roughly 20% in Q3 2025 to roughly 10% in Q3 2026, nearly halving, which points to margin pressure as the main driver of the profit decline rather than sales volume alone.

Press coverage of the first-half 2026 disclosure cited online sales, quasi-drug sales and a price increase from Q2 as profit supports, so the cause of the Q3 profit drop is a point to check in the next annual report notes and management commentary.

05

Industry analysis

The transdermal patch market in which Tdspharm operates, covering cataplasma and plaster products in Korea, was described as roughly KRW 200 billion in size in coverage around the company's 2024 listing.

In the same coverage, the company was cited as the leader in the Korean herbal compound cataplasma market with a 70% share, which suggests a concentrated position in that segment.

The smoking-cessation patch market grew after government cessation-treatment support began in 2015, then shrank after a 2019 impurity incident, reaching about KRW 12 billion in 2022 according to 2024-era reporting.

Coverage from June 2026 said stronger global anti-smoking policies are lifting demand for nicotine replacement therapy, and the company said it is shifting toward higher-value prescription products.

Management also argued that an aging population and rising chronic disease are increasing demand for patch-type therapies that improve dosing convenience.

In cycle terms, 2026 growth appears driven more by company-specific factors such as online channels, quasi-drug sales and a price increase than by a broad sector upturn.

Competitively, Tdspharm benefits from a model in which pharmaceutical companies outsource formulation and production to an ODM partner rather than building their own capacity.

On formulation, the company says its plasters are smaller and thinner than cataplasma, and its hot-melt process avoids organic solvents and reduces skin irritation. Competition in patches is likely to turn on formulation design capability and speed of production response.

06

Outlook

In its August 2026 disclosure commentary, the company said second-half secured volume equals about 90% of first-half sales, and on that basis it expects annual sales growth in the upper-teens percent range year on year.

In the same remarks, the CEO named online market entry, expansion of quasi-drug sales and stronger herbal product competitiveness as second-half growth drivers. On the product schedule, a plaster product is due to launch in Q4 2026, and a fluviprofen plaster is slated to be added to the sales lineup from Q1 2027.

A coin-type plaster has completed production equipment setup and terms are under discussion with several pharmaceutical companies, while a coin-type bug patch is being pursued in supply contracts with multiple pharma partners, as of an October 2026 announcement.

In patches, the company agreed in July 2026 to a preliminary study with a domestic pharma partner on a seven-day buprenorphine patch, and it plans technology-fee or profit-sharing contracts after commercialization.

In June 2026 it signed an MOU with Keimyung University for a joint study of a keloid scar transdermal formulation. Overseas, it launched a Tdspharm-branded product in Uzbekistan for the first time and is pursuing Southeast Asia, Central Asia and the Middle East.

Coverage of the new Osong plant said capacity would expand substantially once expansion is completed, and the completion timing is a point to check in future disclosures.

A 2024-era target to commercialize non-narcotic pain and cancer pain patches in 2027 remains open, and whether it is met will shape how much value the pipeline adds. The next regular report, the 2026 annual report, will show whether annual sales growth and operating margin line up with management's expectations.

07

Valuation

PER
5.2×
PBR
0.5×
ROE
10.2%
EPS
₩799
BPS
₩8,248
Dividend per share
₩0

Valuation multiples should be read against the last four quarters' combined profit attributable to controlling shareholders of KRW 4.42 billion, and because a falling profit base raises the multiple at any given share price, the figures need careful reading.

Profit attributable to controlling shareholders was KRW 4.69 billion in 2023, KRW 3.72 billion in 2024 and KRW 4.27 billion in 2025, so the 2025 recovery still left it below the 2023 level.

The balance sheet at end-2025 showed equity of KRW 42.8 billion, all attributable to controlling shareholders, total liabilities of KRW 11.4 billion and a debt-to-equity ratio of 26.6%, a relatively light debt load. The price-to-book level places the share price at a discount to net asset value.

In a June 2026 interview, the CEO described the price-to-book ratio as low and said the small free float appears to weigh on the share price. On dividends, the cash yield is on the low side, and the CEO said the company plans to expand shareholder returns through dividends and treasury share use. The key to reading the multiple is whether quarterly profit stops declining and recovers.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

First-half top-line growth

The company disclosed first-half 2026 sales of KRW 16.1 billion, up 48% year on year, with online channels, quasi-drug sales and a Q2 price increase cited as drivers. Annual sales in 2025 edged up from KRW 27.5 billion in 2024. Management also said second-half secured volume is about 90% of first-half sales.

Shift toward patch products

The company is adding patch-type prescription products to a cataplasma-centered revenue base. A buprenorphine patch preliminary study agreed in July 2026 and a keloid scar joint study agreed in June 2026 widen the pipeline. The company's plan is to build patches into a higher-value cash generator.

Balance sheet capacity

Total liabilities at end-2025 were KRW 11.4 billion and the debt-to-equity ratio fell to 26.6% from 48.1% in 2023. Operating cash flow stayed in the KRW 3 billion range, at KRW 3.29 billion in 2023, KRW 3.93 billion in 2024 and KRW 3.78 billion in 2025. Equity at end-2025 was KRW 42.8 billion.

09

Bear factors

Four straight quarters of profit decline

Operating profit fell from KRW 1.64 billion in Q3 2025 to KRW 739 million in Q3 2026, with declines in each of the four quarters from Q4 2025 through Q3 2026. Profit attributable to controlling shareholders also fell for three straight quarters to KRW 724 million. The profit decline has been steeper than the sales decline, which signals margin pressure.

Slower top line in Q3

Q3 2026 sales were KRW 7.65 billion, down 5.3% from the prior quarter and down 5.4% year on year. After two quarters stalled near KRW 8 billion, sales slipped further in Q3. Whether the second-half growth expectation shows up in quarterly sales remains to be seen.

Commercialization timing and customer dependence

Most of the patch pipeline is still in research or development. Whether the 2027 commercialization target cited in 2024 coverage holds is uncertain. Because revenue depends on pharmaceutical customers' ODM orders, changes in those orders feed directly into results.

10

Risk factors

Customer concentration and ODM orders

Because most products are supplied to pharmaceutical companies, a change in a key customer's orders directly affects sales. If sales under customer brands fall, orders can fall with them, which limits visibility on revenue. Quarterly sales stalling near KRW 8 billion is consistent with this dependence.

New products and pipeline execution

Prescription patches must pass clinical, approval and manufacturing steps, so the 2027 target from 2024 coverage could slip. The post-commercialization arrangement with the domestic partner is planned as a technology-fee or profit-sharing deal, so the revenue structure is not yet fixed.

Share liquidity and governance

The CEO said the small free float weighs on the share price, which can make the stock move more with supply and demand than with the broader market. At the March 2026 annual general meeting, a director pay-limit resolution failed to reach quorum and was left pending, so governance procedure is also worth checking.

11

What to watch next

  1. November 18, 2026

    The extraordinary general meeting will vote on partial articles amendments, re-election of inside director Lee Young-moo and new appointment of outside director Kang Jin-yang. It is the point to check any change in board composition and governance.

  2. Q4 2026

    Whether the Power RX plaster launches and whether supply contracts for mini plasters and coin-type products are signed. These show how far new products diversify a cataplasma-centered revenue base.

  3. Early 2027 (Q4 2026 results)

    Whether Q4 2026 sales and operating profit break the run of four consecutive quarterly declines. It is the test of whether the Q3 margin drop persists.

  4. Q1 2027

    The start of sales for the fluviprofen plaster under the consignment sales agreement, and whether it shows up as revenue.

  5. Around late March 2027

    The 2026 annual report. It will show whether annual sales growth matches the upper-teens expectation and how the quarterly profit decline is reflected in the full-year operating margin.

12

Overall view

Tdspharm is a patch-focused contract manufacturer and ODM specialist built on transdermal drug delivery, with cataplasma and plaster products at its core. Annual sales were KRW 27.6 billion in 2025, still below the KRW 30 billion of 2023 but above the 2024 low of KRW 27.5 billion.

The operating margin fell from 16.7% in 2023 to 13.6% in 2024 and held there in 2025, and Q3 2026 operating profit was down 54.9% year on year. Profit attributable to controlling shareholders has declined for three straight quarters since its Q4 2025 peak, and the last four quarters total KRW 4.42 billion.

On the other side, first-half 2026 sales rose 48% year on year to KRW 16.1 billion, and new products, pharmacy distribution and online channels are being positioned as new growth bases. The balance sheet is a stabilizing factor, with a 26.6% debt-to-equity ratio and operating cash flow in the KRW 3 billion range.

The patch pipeline is still mostly in research, so the timing of any profit contribution is uncertain, and how the multiple reads depends on whether earnings recover.

The next checkpoints are the extraordinary general meeting on November 18, 2026, the Q4 2026 product launches, and the 2026 annual report's growth and margin figures.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. saramin.co.kr
  2. specialtimes.co.kr
  3. pinpointnews.co.kr
  4. thedailypost.kr
  5. pharm.edaily.co.kr
  6. pharmnews.com
  7. edaily.co.kr
  8. pharm.edaily.co.kr
  9. straightnews.co.kr
  10. press9.kr
  11. thedailypost.kr
  12. kormedi.com
  13. fnnews.com
  14. newspim.com
  15. fnnews.com
  16. m.news.nate.com
  17. seoulexchange.kr
  18. markets.hankyung.com

Report written 2026-11-13 · Data as of 2026-11-12

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis